Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

Sponsor
AstraZeneca
Study ID
NCT01029886
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • exenatide once weekly — DRUG
    subcutaneous injection, 2mg, once weekly
  • liraglutide — DRUG
    subcutaneous injection, forced titration to 1.8mg, once daily

Study Details

No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight, subject-reported outcomes, and other clinical benefits. The study includes a 26-week treatment period and a safety follow-up visit 10 weeks after the final study drug dose.

Key Dates

First listed
Dec 10, 2009
Start date
Jan 31, 2010
Status verified
Mar 2015
Primary completion
Jan 31, 2011
Completion
Apr 30, 2011

Study Design

Enrollment
912 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 1
  • Active Comparator: 2

Primary Outcome Measure

Change in HbA1c From Baseline to Week 26 [ Time Frame: Baseline, Week 26 ]

Find similar trials

Nationwide
Type 2 diabetes trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies